Neuroendocrine tumors (NETs) of the stomach are rare cancers originating from neuroendocrine cells that produce hormones regulating digestion. These tumors are categorized as functional or non-functional based on whether they secrete hormones that cause symptoms. Functional stomach NETs can lead to hormonal imbalances with noticeable clinical effects, while non-functional NETs typically grow slowly and remain asymptomatic until they reach advanced stages. Stomach NETs are classified using the TNM staging system, which evaluates tumor size, depth of invasion into the stomach wall, involvement of nearby lymph nodes, and distant metastasis. Tumor grades, which reflect growth rate and aggressiveness, range from Grade 1 (low-grade, slow-growing tumors with better prognosis), to Grade 2 (intermediate growth rate), and Grade 3 (high-grade neuroendocrine carcinomas that are fast-growing and aggressive). In terms of staging, Stage I tumors are limited to the inner layers of the stomach without lymph node involvement, Stage II tumors have penetrated deeper layers but still lack lymph node spread, Stage III tumors show regional lymph node involvement, and Stage IV disease is characterized by distant metastases, commonly to the liver or peritoneum.

Several factors increase the risk of developing neuroendocrine tumors (NETs) of the stomach. Chronic gastritis caused by Helicobacter pylori infection is a major contributor, as the persistent inflammation it causes can promote tumor development. Zollinger-Ellison syndrome, characterized by gastrin-producing tumors called gastrinomas, is also linked to an elevated risk of stomach NETs due to excessive gastric acid production. Genetic conditions like Multiple Endocrine Neoplasia Type 1 (MEN1) significantly raise the likelihood of developing various endocrine tumors, including those in the stomach. Age and gender play a role as well, with stomach NETs occurring more frequently in individuals over 50 and showing a slight predominance in men. A family history of gastrinomas or other neuroendocrine tumors may further increase risk, suggesting hereditary factors. Additionally, lifestyle factors such as smoking and alcohol use, which are known to contribute to general stomach cancer risk, may also influence the development of stomach NETs by affecting hormone production or causing chronic gastric irritation.

Symptoms of stomach neuroendocrine tumors (NETs) vary depending on whether the tumor is functional, meaning it secretes hormones, or non-functional, which do not produce hormones and often remain silent until advanced. Functional tumors cause symptoms related to hormone overproduction: for example, gastrinomas secrete excessive gastrin, leading to Zollinger-Ellison Syndrome characterized by severe acid reflux, difficult-to-heal stomach ulcers, diarrhea, and weight loss. In rare cases, carcinoid syndrome can occur, causing facial flushing, diarrhea, abdominal cramping, and wheezing or shortness of breath. VIPomas, which produce vasoactive intestinal peptide, cause severe watery diarrhea, dehydration, and low potassium levels. Non-functional tumors, by contrast, often go unnoticed initially and are discovered incidentally during imaging for other reasons. When symptoms do arise, they tend to be related to tumor growth or spread and may include abdominal pain or discomfort, loss of appetite, unexplained weight loss, bloating, nausea, vomiting, difficulty swallowing if the tumor obstructs the stomach, and jaundice if the cancer has metastasized to the liver.

Diagnosis of stomach neuroendocrine tumors (NETs) involves a combination of imaging, blood tests, and biopsy to accurately identify and characterize the tumor. Imaging tests such as CT or MRI scans are used to determine the tumors size, location, and whether it has spread to nearby organs or lymph nodes. Endoscopic ultrasound (EUS) provides detailed visualization of tumors within the stomach lining and allows for guided biopsies. Specialized imaging like Octreoscan (somatostatin receptor scintigraphy) and PET/CT scans using Gallium-68 DOTATATE help detect tumors that express somatostatin receptors, improving the sensitivity of locating primary and metastatic lesions. Blood tests measure biomarkers such as Chromogranin A (CgA), which is elevated in many NETs, as well as hormone-specific assays like gastrin levels for gastrinomas, vasoactive intestinal peptide (VIP) for VIPomas, and 24-hour urine 5-HIAA for serotonin-producing carcinoid syndrome. Definitive diagnosis is confirmed through an endoscopic biopsy, where tissue samples are microscopically examined to determine tumor type, grade, and aggressiveness, which are essential for treatment planning.

Treatment of stomach neuroendocrine tumors (NETs) is tailored based on the tumors size, location, grade, stage, and whether it is functional or non-functional. Surgery is often the primary approach, ranging from local resection of the tumor with a margin of healthy tissue to partial gastric resection if the tumor is large or affecting stomach function. If the cancer has spread to nearby lymph nodes, lymph node dissection is performed, and in cases of liver metastases confined to one area, surgical removal of those lesions may be considered. For functional tumors, somatostatin analogs like octreotide and lanreotide are used to control hormone secretion and slow tumor growth. Peptide receptor radionuclide therapy (PRRT), such as Lutathera (Lutetium-177 DOTATATE), provides targeted radiation to tumors expressing somatostatin receptors, offering an effective option for advanced disease. Targeted therapies like everolimus and sunitinib inhibit molecular pathways involved in tumor growth and are typically reserved for progressive or metastatic NETs. Chemotherapy with agents such as cisplatin and etoposide is usually reserved for high-grade, aggressive neuroendocrine carcinomas. For liver metastases, liver-directed treatments such as radiofrequency ablation (RFA) and transarterial embolization (TAE) can help control tumor burden by destroying or starving tumors of their blood supply.

Stomach neuroendocrine tumors (NETs) cannot always be prevented, certain measures may help reduce the risk or facilitate early detection. Treating Helicobacter pylori infections is important, as this bacterium is a known cause of chronic gastritis that can increase the likelihood of gastric cancers, including NETs. Maintaining a healthy diet rich in fiber, fruits, and vegetables, while limiting processed meats, supports overall gastric health and may lower cancer risk. Avoiding smoking and excessive alcohol consumption is also crucial, as both are established contributors to stomach cancer development. Individuals with genetic conditions like Multiple Endocrine Neoplasia type 1 (MEN1) or Zollinger-Ellison syndrome should undergo regular screening and surveillance, as they are at higher risk for developing NETs. Routine medical checkups and prompt evaluation of symptoms can aid in early diagnosis, which significantly improves treatment outcomes and prognosis.

Current research on stomach neuroendocrine tumors (gNETs) is focused on improving early detection, treatment, and outcomes through several promising avenues. Advanced somatostatin receptor imaging techniques like SSTR-PET/CT are enhancing tumor detection and staging. Genetic testing is helping identify markers such as CXCR4, which may guide targeted therapies, especially in aggressive tumors with low somatostatin receptor expression. Immunotherapy trials are exploring checkpoint inhibitors to boost the immune response against high-grade tumors. Additionally, new peptide receptor radionuclide therapy (PRRT) agents are being developed to provide more effective, personalized treatment options. Together, these advances aim to offer more precise diagnostics and better therapeutic strategies for patients with stomach NETs.

1. Are stomach NETs aggressive? Low-grade stomach NETs tend to grow slowly and usually have a better prognosis. However, high-grade neuroendocrine carcinomas (NECs) are aggressive and often require chemotherapy. 2. What is the survival rate for stomach NETs? Survival varies by stage: localized tumors (Stage I-II) have a 5-year survival rate of 80-90%, lymph node spread (Stage III) drops survival to 50-70%, and metastatic disease (Stage IV) has a 20-40% 5-year survival rate. 3. Can stomach NETs be cured? Yes, when detected early, localized stomach NETs can often be completely removed with surgery, offering a chance for cure. 4. What are the best treatments for functional NETs? Somatostatin analogs, like Octreotide, are very effective in controlling hormone-related symptoms caused by functional stomach NETs. 5. What is the difference between gastric NETs and gastric adenocarcinoma? Gastric NETs originate from neuroendocrine cells and generally have a different, often less aggressive course compared to gastric adenocarcinoma, which arises from glandular cells and tends to be more aggressive.